Purvalanol A
Overview | |
Catalog # | bs-7023c-10mg-solid |
Product Name | Purvalanol A |
Specifications | |
Storage Buffer | Powder |
Storage Condition | Store in dry, dark place at -20C for 1 year. |
Target | |
Product Information | Molecular Weight: 388.89 Formula: C19 H25 Cl N6 O CAS Number: 212844-53-6 InChi Key: PMXCMJLOPOFPBT-HNNXBMFYSA-N InChi: InChI=1S/C19H25ClN6O/c1-11(2)15(9-27)23-19-24-17(22-14-7-5-6-13(20)8-14)16-18(25-19)26(10-21-16)12(3)4/h5-8,10-12,15,27H,9H2,1-4H3,(H2,22,23,24,25)/t15-/m0/s1 Smiles: CC(C)N1C=NC2=C1N=C(N[C@@H](CO)C(C)C)N=C2NC1=CC(Cl)=CC=C1 Purity: 98.0 Solubility: Soluble in DMSO Appearance: Solid Power. Shelf Life: 1.0 years |
Description | Purvalanol A is a potent CDK inhibitor, which effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src. indicating that the activation of CDKs contributes to the c-Src transformation. Purvalanol A suppressed the c-Src activity as effectively as the Src-selective inhibitor PP2, and that it reverted the transformed morphology to a nearly normal shape with less cytotoxicity than PP2. Purvalanol A induced a strong G2-M arrest, whereas PP2 weakly acted on the G1-S transition. Furthermore, when compared with PP2, purvalanol A more effectively suppressed the growth of human colon cancer HT29 and SW480 cells, in which Src family kinases and CDKs are activated. |